Columbia Labs ticks up revenue; Chiltern rebrands after M&A;

> Columbia Laboratories ($CBRX) boosted its quarterly revenue by 61%, bringing in $11.5 million as it transitions into a hybrid business model. More

> Chiltern has rebranded itself after a series of restructuring moves, and the CRO now employs more than 2,200 workers in 45 countries, covering all phases of drug development. News

Suggested Articles

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.